Moderna’s Australian mRNA manufacturing facility set to become operational in 2024

By Rachel Arthur

- Last updated on GMT


Related tags Moderna Australia mRNA

Moderna has finalized a strategic partnership with the Australian government to build an mRNA manufacturing facility in Melbourne: which is expected to produce up to 100 million mRNA respiratory vaccine doses annually.

The facility will provide a domestically manufactured portfolio of mRNA vaccines against respiratory viruses: including COVID-19, seasonal influenza, respiratory syncytial virus (RSV), and other potential respiratory viruses, pending licensure.

Under the terms of the 10-year agreement, Moderna will develop and commission the facility, and expects to create hundreds of jobs during construction and operation. Construction is expected to commence by the end of this year, with the facility expected to become operational by the end of 2024.

This week’s announcement finalizes an agreement made in principle for an Australian site made in December last year.

"We are delighted to reach this milestone with the Australian Government and finalize our first on-shore manufacturing agreement," ​said Stéphane Bancel, Chief Executive Officer of Moderna. "The Australian Federal Government has been a great partner, and we are pleased to expand this partnership to support Australia's mRNA life sciences ecosystem and global public health."

As part of the partnership, Moderna pledges to support Australia's mRNA research, development, and industry ecosystem, including engagement with collaborative research partnerships with Australian institutions and establishing a Regional Research Centre for respiratory medicines and tropical diseases.

Moderna's mRNA pipeline includes 28 vaccine candidates, including vaccines against respiratory viruses, vaccines against latent viruses, and vaccines against threats to global public health.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Related suppliers

Follow us


View more